ストックスクリーナーアプリを入手
3.89
1.27%
-0.05
プレマーケット:
3.85
-0.04
-1.03%
前日終値:
$3.94
開ける：
$3.95
24時間の取引高:
3.56M
Relative Volume:
0.62
時価総額：
$1.20B
収益：
$360.78M
当期純損益:
$-23.91M
株価収益率:
-49.81
EPS:
-0.0781
ネットキャッシュフロー:
$13.07M
1週間 パフォーマンス:
-2.75%
1か月 パフォーマンス:
+15.09%
6か月 パフォーマンス:
-35.06%
1年 パフォーマンス:
+3.18%
1日の値動き範囲:
$3.88
$4.06
1週間の範囲:
$3.83
$4.06
52週間の値動き範囲:
$2.23
$6.51
Mannkind Corp Stock (MNKD) Company Profile
Compare MNKD vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
3.89 | 1.22B | 360.78M | -23.91M | 13.07M | -0.0781 |
VRTX
Vertex Pharmaceuticals Inc
|
466.79 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.50 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
903.75 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.41 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
165.81 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-27 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-11-13 | 開始されました | Leerink Partners | Outperform |
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-10-10 | 開始されました | Leerink Partners | Outperform |
| 2025-07-16 | 再開されました | H.C. Wainwright | Buy |
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-02-10 | 開始されました | Wedbush | Outperform |
| 2024-12-20 | 開始されました | Wells Fargo | Overweight |
| 2024-12-19 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-06-13 | 開始されました | Rodman & Renshaw | Buy |
| 2023-10-10 | 開始されました | Wedbush | Outperform |
| 2021-05-14 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | 開始されました | Oppenheimer | Outperform |
| 2019-10-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-05-14 | 開始されました | BTIG Research | Buy |
| 2019-03-04 | 開始されました | SVB Leerink | Outperform |
| 2019-02-22 | 開始されました | SVB Leerink | Outperform |
| 2018-02-28 | ダウングレード | Maxim Group | Hold → Sell |
| 2017-11-01 | ダウングレード | Maxim Group | Buy → Hold |
| 2017-10-10 | 開始されました | H.C. Wainwright | Buy |
| 2017-10-06 | 繰り返されました | Maxim Group | Buy |
| 2017-08-11 | 開始されました | Maxim Group | Buy |
| 2016-05-10 | 繰り返されました | Piper Jaffray | Underweight |
| 2016-05-10 | 繰り返されました | RBC Capital Mkts | Underperform |
| 2016-01-06 | 繰り返されました | Piper Jaffray | Underweight |
| 2016-01-06 | 繰り返されました | RBC Capital Mkts | Underperform |
| 2015-11-04 | ダウングレード | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | ダウングレード | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2015-05-11 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2015-05-11 | 繰り返されました | MLV & Co | Hold |
| 2015-04-16 | 繰り返されました | RBC Capital Mkts | Outperform |
すべてを表示
Mannkind Corp (MNKD) 最新ニュース
MannKind Corp (MNKD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MannKind Corp (MNKD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MannKind Corp (MNKD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MNKD Stock Price, Quote & Chart - ChartMill
MannKind Corp (MNKD) Valuation: PE, PB & Fair Value Analysis - TradingKey
MannKind Corp (MNKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MannKind Corp (MNKD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MannKind Corp (MNKD) Institutional Confidence - TradingKey
MannKind Corp (MNKD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MannKind Corp (MNKD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q1 2026 MannKind Corp Earnings Call Transcript - GuruFocus
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story” - Insider Monkey
MANNKIND CORP (MNKD) Stock Chart - ChartMill
7 Hidden Penny Stocks to Invest In - Insider Monkey
MannKind (MNKD) Stock And Valuation After New Afrezza And FUROSCIX Clinical Data - Yahoo Finance
MannKind (MNKD) Stock Price, News & Analysis - MarketBeat
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children - Stocktwits
Jim Cramer Says He Blessed MannKind as a Speculation Only - Insider Monkey
MannKind highlights wider role for Afrezza at ADA 2026 - The Pharma Letter
Jim Cramer Puts This Chip Stock In The 'Penalty Box,' Warns Occidental Could 'Go Down A Lot' If War Ends - Sahm
Jim Cramer Highlighted 16 Stocks Including Quantinuum, and the Market’s Appetite for New Supply - Insider Monkey
MannKind shares more data backing inhaled insulin - Drug Delivery Business
New data affirm safety and efficacy of MannKind's Afrezza inhaled insulin for children and adults with diabetes. - Pluang
MannKind Corporation Presents New Clinical Data Supporting Afrezza and FUROSCIX at ADA 2026 Scientific Sessions - Quiver Quantitative
Inhaled insulin data explore options for kids, pregnancy and pump users - Stock Titan
MannKind (MNKD) Advances Clinical Trials for Inhaled IPF Therapy - Insider Monkey
MannKind Corp stock (US5638651064): focus on valuation metrics after recent FDA and partnership news - AD HOC NEWS
Earnings call transcript: MannKind Q1 2026 sees revenue growth, stock surges - Investing.com
MNKD Stock Heads For Strongest Month In Over Three Years As FDA Catalyst Draws Closer - Stocktwits
Assessing MannKind (MNKD) Valuation After Recent Share Price Momentum And Royalty Growth Expectations - simplywall.st
MannKind develops inhaled ralinepag formulation for United Therapeutics - Investing.com
MannKind Q1 2026 slides: revenue up 15%, three catalysts ahead - Investing.com
MannKind stock surges on United Therapeutics partnership deal - Investing.com
5 Most Promising Penny Stocks According to Wall Street Analysts - Insider Monkey
MannKind (MNKD) Announces Milestones in Nintedanib DPI Development for IPF - GuruFocus
MannKind (MNKD) Announces Milestones in Nintedanib DPI Developme - GuruFocus
MannKind completes patient enrollment in nintedanib DPI trials - Investing.com
MannKind Corporation Advances Nintedanib DPI Program for IPF with Phase 1b INFLO-1 Study Data Expected in Q3 2026 - Quiver Quantitative
MannKind tests inhaled IPF drug in global trial, first data Q3 2026 - Stock Titan
FDA approves MannKind’s Afrezza inhaled insulin for children with diabetes - Investing.com
FDA clears MannKind (NASDAQ: MNKD) Afrezza use in children 6 and older - Stock Titan
MannKind At An Inflection Point: Pediatric Expansion Drives The Story (NASDAQ:MNKD) - Seeking Alpha
MannKind Corp stock (US5638651064): Afrezza pediatric FDA approval and share price weakness draw foc - AD HOC NEWS
MannKind (MNKD) Is Up 11.5% After Afrezza Pediatric Approval And Trial ReliefHas The Bull Case Changed? - Yahoo Finance
MNKD stock eyes best month since 2022 ahead of FDA decision on pediatric diabetes treatment - MSN
symbol__ Stock Quote Price and Forecast - CNN
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market - Barchart.com
FDA approves Afrezza for children and adolescents with diabetes - Managed Healthcare Executive
US FDA approves MannKind's inhaled insulin for children - Reuters
MannKind Corporation (MNKD) Receives FDA Approval for Pediatric Use of Afrezza - GuruFocus
Mannkind Corp (MNKD) 財務データ
収益
当期純利益
現金流量
EPS
0.57%
1.15%
大文字化:
|
ボリューム (24 時間):